PaxMedica, Inc. Stock price

Equities

PXMD

US70424C2035

Biotechnology & Medical Research

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
0.51 USD -4.67% Intraday chart for PaxMedica, Inc. -17.07% -32.63%
Sales 2024 * - Sales 2025 * - Capitalization 3.78M
Net income 2024 * -12M Net income 2025 * - EV / Sales 2024 * -
Net cash position 2024 * - Net cash position 2025 * - EV / Sales 2025 * -
P/E ratio 2024 *
-0.47 x
P/E ratio 2025 *
-
Employees 7
Yield 2024 *
-
Yield 2025 *
-
Free-Float 36.45%
More Fundamentals * Assessed data
Dynamic Chart
1 day-4.67%
1 week-17.07%
Current month-19.05%
1 month-19.51%
3 months-35.30%
6 months-89.62%
Current year-32.63%
More quotes
1 week
0.50
Extreme 0.5
0.62
1 month
0.50
Extreme 0.5
1.05
Current year
0.37
Extreme 0.372
1.05
1 year
0.37
Extreme 0.372
40.40
3 years
0.37
Extreme 0.372
178.16
5 years
0.37
Extreme 0.372
178.16
10 years
0.37
Extreme 0.372
178.16
More quotes
Managers TitleAgeSince
Chief Executive Officer 65 20-03-03
Director of Finance/CFO 44 22-06-30
Chief Tech/Sci/R&D Officer 67 23-08-15
Members of the board TitleAgeSince
Director/Board Member 78 22-09-30
Chief Executive Officer 65 20-03-03
Director/Board Member 40 19-02-28
More insiders
Date Price Change Volume
24-03-28 0.51 -4.67% 92,866
24-03-27 0.535 +4.74% 49,251
24-03-26 0.5108 -11.01% 144,874
24-03-25 0.574 +4.02% 49,831
24-03-22 0.5518 -10.28% 59,624

Delayed Quote Nasdaq, March 28, 2024 at 04:30 pm EDT

More quotes
PaxMedica, Inc. is a clinical-stage biopharmaceutical company. The Company is focusing on the development of anti-purinergic drug therapies (APT) for the treatment of disorders with intractable neurologic symptoms, ranging from neurodevelopmental disorders, including autism spectrum disorder (ASD), to neurodegenerative disorders, such as Fragile X Tremor Ataxia Syndrome (FXTAS) and post-viral Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS), a debilitating physical and cognitive disorder believed to be viral in origin and with rising incidence globally due to the long-term effects of SARS-CoV-2 (COVID-19). Its lead program PAX-101 is an intravenous formulation of suramin, in the treatment of ASD and the advancement of the clinical understanding of using that agent against other disorders fragile X syndrome (FXS), FXTAS, ME/CFS and Long COVID-19 Syndrome (LCS), a clinical diagnosis in individuals who have been previously infected with COVID-19.
More about the company
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
0.51 USD
Average target price
3 USD
Spread / Average Target
+488.24%
Consensus
  1. Stock
  2. Equities
  3. Stock PaxMedica, Inc. - Nasdaq